Response of canine transmissible venereal tumor to vincristine sulfate and vinblastine sulfate chemotherapy
ABSTRACT. Ramadinha R.R., Teixeira R.S., Bomfim P.C., Mascarenhas M.B., França T.N., Peixoto T.C., Costa S.Z.R. & Peixoto P.V. [Response of canine transmissible venereal tumor to vincristine sulfate and vinblastine sulfate chemotherapy.] Resposta do tumor venéreo transmissível canino à quimioterapia com sulfato de vincristina e vimblastina. Revista Brasileira de Medicina Veterinária 38(Supl.1):65-69, 2016. Departamento de Medicina e Cirurgia Veterinária, Instituto de Veterinária, Universidade Federal Rural do Rio de Janeiro, Rodovia BR 465 Km 7, Seropédica, RJ 23851-970, Brasil. E-mail: firstname.lastname@example.org From 165 dogs, males and females, affected by the transmissible venereal tumor (TVT), 103 were submitted to therapy protocols with vincristine sulfate - VC - (0.025 mg/kg) and 62 with vinblastine sulfate - VB - (2.5 mg/m2 ). The drugs were administered intravenously once a week. From the animals treated with VC, 65 received a complete treatment and 64 (98.46%) were cured. Fifty eight dogs (89.23%) had complete regression with one to six VC injections until the total remission of the tumor. Only six dogs (9.23%) had to receive seven to ten VC applications. Thirty-eight dogs (36.89%) had their treatment abandoned after one to three VC applications, in general when presented partial involution of the neoplasia. Of those 62 treated with VB, 36 dogs had the treatment completed with total remission (100%) of the neoplasia. Thirty two animals (88.89%) needed one to six applications, while 4 dogs (11.11%) needed seven to eight doses to eliminate the tumors. It was concluded that both VC as VB are effective however, the VC should remain the drugs of choice for its low cost compared to VB, which, however, should be the drug of choice when the VC is not viable. Side effects characterized by vomiting, loss of appetite and diarrhea, as well as hematological disorders were considered mild and it do not preclude the use of both drugs.
Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Creative Commons Attribution License (CC BY-NC 4.0), allowing the sharing of work with acknowledgement of the authorship of the work and initial publication in this journal. They may take additional contracts separately, with acknowledgement of authorship and initial publication in this journal. They are authorized to publish and distribute their work online after publication by BJVM.
The AUTHOR is informed and agrees with the journal that, therefore, its article may be incorporated into existing databases and scientific information systems (indexers and current databases) or existing in the future (indexers and future databases), under the conditions defined by the latter at all times, which shall at least involve the possibility that the holders of these databases may perform the following actions on the article: Reproduce, transmit and distribute the article, in whole or in part in any form or means of electronic transmission existing or developed in the future, including electronic transmission for research, viewing and printing purposes; extract figures, tables, illustrations, and other graphic objects, and capture metadata, captions, and related articles for search, preview, and print purposes. Scan and/or store images and electronic article text.